Davidson Michael H. 4
4 · NewAmsterdam Pharma Co N.V. · Filed Feb 26, 2026
Research Summary
AI-generated summary of this filing
NewAmsterdam (NAMS) CEO Michael H. Davidson Exercises Options, Sells 306k Shares
What Happened
- Michael H. Davidson, CEO of NewAmsterdam Pharma Co. N.V., exercised stock options and sold the resulting shares in open-market transactions between Feb 24–26, 2026. He exercised a total of 306,293 option-based shares (64,708 on Feb 24; 58,253 on Feb 25; 183,332 on Feb 26) and sold the same number of ordinary shares.
- The sales totaled 306,293 shares for aggregate proceeds of approximately $10,575,092 (weighted averages by day/prices reported: $35.43–$36.74 ranges across trades; reported per-trade totals: Feb 24 ≈ $2.34M, Feb 25 ≈ $2.06M, Feb 26 ≈ $6.18M).
- These filings show exercises (derivative code M) followed by sales (code S) of the same share counts — consistent with an exercise plus immediate sale (commonly a cashless exercise). The option exercise price is EUR 1.16392 per share.
Key Details
- Transaction dates: Feb 24–26, 2026. Sales weighted-average prices and per-day totals:
- Feb 24: 64,708 shares sold (split entries) — ~$2,338,943 (prices ranged ≈ $35.43–$36.42)
- Feb 25: 58,253 shares sold (split entries) — ~$2,056,175 (prices ranged ≈ $34.57–$36.74)
- Feb 26: 183,332 shares sold (split entries) — ~$6,179,974 (prices ranged ≈ $33.34–$34.82)
- Total sold: 306,293 shares for ~$10.6M.
- Notable footnotes:
- F1: Exercise price = EUR 1.16392.
- F10: Options were granted Nov 22, 2022 (replacement of a July 6, 2021 grant); vesting schedule described (25% vested Aug 1, 2021; remainder monthly over 3 years subject to continued service).
- F2–F8: Reported prices are weighted averages; per-trade sale-price ranges are provided in the filing.
- F9: Separately, 285,715 ordinary shares were transferred by Davidson into the "Michael H. Davidson 2026 Grantor Retained Annuity Trust" (GRAT) on Feb 26, 2026; that transfer was exempt from Section 16 reporting under Rule 16a-13. Davidson is sole annuitant and trustee.
- Shares owned after these transactions: not specified in the provided excerpt of the filing.
- Filing timeliness: filing date Feb 26, 2026 (covers transactions Feb 24–26); the filing itself does not indicate a late/untimely status in the provided data.
Context
- For retail investors: these transactions reflect option exercises followed by open-market sales that converted vested equity into cash for the insider. Such exercises plus immediate sales are common for liquidity (and tax) management and do not by themselves indicate the insider’s view of the company’s long-term prospects.
- The GRAT transfer is a non-sale estate-planning action and was reported as exempt from Section 16 obligations; transfers into trusts/gifts are generally not market-sentiment signals.
Insider Transaction Report
Form 4
Davidson Michael H.
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Ordinary Shares
[F1]2026-02-24+64,708→ 524,567 total - Sale
Ordinary Shares
[F2]2026-02-24$36.13/sh−61,547$2,223,693→ 463,020 total - Sale
Ordinary Shares
[F3]2026-02-24$36.46/sh−3,161$115,250→ 459,859 total - Exercise/Conversion
Ordinary Shares
[F1]2026-02-25+58,253→ 518,112 total - Sale
Ordinary Shares
[F4]2026-02-25$35.11/sh−46,517$1,633,212→ 471,595 total - Sale
Ordinary Shares
[F5]2026-02-25$35.96/sh−10,436$375,279→ 461,159 total - Sale
Ordinary Shares
[F6]2026-02-25$36.68/sh−1,300$47,684→ 459,859 total - Exercise/Conversion
Ordinary Shares
[F1]2026-02-26+183,332→ 643,191 total - Sale
Ordinary Shares
[F7]2026-02-26$33.63/sh−165,408$5,562,671→ 477,783 total - Sale
Ordinary Shares
[F8][F9]2026-02-26$34.44/sh−17,924$617,303→ 174,144 total - Exercise/Conversion
Option (right to buy)
[F1][F10]2026-02-24−64,708→ 924,559 totalExp: 2031-07-06→ Ordinary Shares (64,708 underlying) - Exercise/Conversion
Option (right to buy)
[F1][F10]2026-02-25−58,253→ 866,306 totalExp: 2031-07-06→ Ordinary Shares (58,253 underlying) - Exercise/Conversion
Option (right to buy)
[F1][F10]2026-02-26−183,332→ 682,974 totalExp: 2031-07-06→ Ordinary Shares (183,332 underlying)
Holdings
- 285,715(indirect: By GRAT)
Ordinary Shares
[F9]
Footnotes (10)
- [F1]The exercise price of the option is EUR 1.16392.
- [F10]The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.43 to $36.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.43 to $36.50 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- [F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.57 to $35.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- [F5]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.57 to $36.55 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- [F6]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.58 to $36.74 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- [F7]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.34 to $34.33 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- [F8]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.35 to $34.82 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- [F9]The amount reported in Column 5 reflects the transfer of 285,715 ordinary shares from the Reporting Person to the Michael H. Davidson 2026 Grantor Retained Annuity Trust (the "GRAT") on February 26, 2026, which transfer was exempt from Section 16 pursuant to Rule 16a-13 under the Securities Exchange Act of 1934. The Reporting Person is the sole annuitant and trustee of the GRAT.
Signature
/s/ Michael H. Davidson|2026-02-26